Iambic prices $150 million IPO at $16 a share
Iambic Therapeutics raised $150 million in an initial public offering on Wednesday, selling about 9.4 million shares at $16 each to begin trading on t
Revolution Medicines
Every Fin-node story mentioning Revolution Medicines — 2 stories, newest first.
Revolution Medicines · 2 stories
Revolution Medicines secures first broad RAS approval in pancreatic cancer
The FDA cleared Revolution Medicines' RASONQUE on August 26, making it the first broad RAS-targeted therapy for metastatic pancreatic adenocarcinoma.